N. Ranjitkar Manandhar, G. K. Kayastha, and P. K. Acharya, “Dasatinib tyrosine kinase inhibitor as second and third line therapy in chronic myeloid leukemia: outcome of a Nepalese study”, JPAHS, vol. 5, no. 1, pp. 47–56, Jul. 2018.